Login to Your Account


Delinia Inc.'s $35 million series A sets up the Cambridge, Mass.-based startup to drive straight down the fairway in targeting regulatory T cells (Tregs) to treat autoimmune diseases. Sofinnova Partners and Atlas Venture were co-leads in the round, with Atlas venture partner Saurabh Saha named president and CEO.

To name a company Visionary Pharmaceuticals Inc. and refer to the leadership team as "world changers" takes a certain degree of confidence.

SHANGHAI – Newly created oncology biotech, CBT Pharmaceuticals, of Santa Clara, Calif., has received $9.75 million in series A financing from venture investors led by Orbimed Healthcare Fund Management Asia, with an additional $2 million available in warrants.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: